Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE45.1450
- TODAY'S CHANGE (%)0.7350 (1.6550%)
- Bid / Lots45.1300/ 4
- Ask / Lots45.1700/ 3
- Open / Previous Close44.8700 / 44.4100
- Day Range
- 52 Week Range
- Volume795,009
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 6554 | 44.765 |
| 09:34 ET | 1801 | 44.86 |
| 09:36 ET | 3203 | 45.465 |
| 09:38 ET | 2769 | 45.18 |
| 09:39 ET | 2581 | 45.525 |
| 09:41 ET | 2275 | 45.56 |
| 09:43 ET | 936 | 45.67 |
| 09:45 ET | 4269 | 45.99 |
| 09:48 ET | 1185 | 45.92 |
| 09:50 ET | 1359 | 45.96 |
| 09:52 ET | 8658 | 45.85 |
| 09:54 ET | 1600 | 45.82 |
| 09:56 ET | 11494 | 45.9 |
| 09:57 ET | 4794 | 46.485 |
| 09:59 ET | 11114 | 46.345 |
| 10:01 ET | 11933 | 46.29 |
| 10:03 ET | 1900 | 46.125 |
| 10:06 ET | 2820 | 46.17 |
| 10:08 ET | 4540 | 46.225 |
| 10:10 ET | 1406 | 46.255 |
| 10:12 ET | 1805 | 46.28 |
| 10:14 ET | 2058 | 46.215 |
| 10:15 ET | 3200 | 46.215 |
| 10:17 ET | 4800 | 46.19 |
| 10:19 ET | 3300 | 46.08 |
| 10:21 ET | 1100 | 46.08 |
| 10:24 ET | 1600 | 46.09 |
| 10:26 ET | 2952 | 46.065 |
| 10:28 ET | 4499 | 46.07 |
| 10:30 ET | 6271 | 45.995 |
| 10:32 ET | 5190 | 46 |
| 10:33 ET | 1800 | 46 |
| 10:35 ET | 11937 | 45.97 |
| 10:37 ET | 1600 | 45.995 |
| 10:39 ET | 4953 | 45.855 |
| 10:42 ET | 6125 | 45.94 |
| 10:44 ET | 7273 | 46.27 |
| 10:46 ET | 1659 | 46.46 |
| 10:48 ET | 2650 | 46.42 |
| 10:50 ET | 4246 | 46.38 |
| 10:51 ET | 5732 | 46.39 |
| 10:53 ET | 600 | 46.42 |
| 10:55 ET | 6138 | 46.51 |
| 10:57 ET | 884 | 46.545 |
| 11:00 ET | 9616 | 46.635 |
| 11:02 ET | 5738 | 46.57 |
| 11:04 ET | 1150 | 46.575 |
| 11:06 ET | 4500 | 46.665 |
| 11:08 ET | 5305 | 46.665 |
| 11:09 ET | 4230 | 46.63 |
| 11:11 ET | 8237 | 46.71 |
| 11:13 ET | 8083 | 46.99 |
| 11:15 ET | 43585 | 47.09 |
| 11:18 ET | 13190 | 46.72 |
| 11:20 ET | 2512 | 46.78 |
| 11:22 ET | 1150 | 46.77 |
| 11:24 ET | 3641 | 46.86 |
| 11:26 ET | 2585 | 46.64 |
| 11:27 ET | 2650 | 46.71 |
| 11:29 ET | 2437 | 46.565 |
| 11:31 ET | 3050 | 46.16 |
| 11:33 ET | 1500 | 46.17 |
| 11:36 ET | 2003 | 46.14 |
| 11:38 ET | 3423 | 45.96 |
| 11:40 ET | 1200 | 45.855 |
| 11:42 ET | 1735 | 45.66 |
| 11:44 ET | 3889 | 45.39 |
| 11:45 ET | 17785 | 45.29 |
| 11:47 ET | 11005 | 45.32 |
| 11:49 ET | 300 | 45.53 |
| 11:51 ET | 2139 | 45.26 |
| 11:54 ET | 100 | 45.46 |
| 11:56 ET | 1739 | 45.18 |
| 11:58 ET | 700 | 45.26 |
| 12:00 ET | 463 | 45.27 |
| 12:02 ET | 21736 | 45.55 |
| 12:03 ET | 1115 | 45.54 |
| 12:05 ET | 100 | 45.55 |
| 12:07 ET | 761 | 45.39 |
| 12:09 ET | 4455 | 44.99 |
| 12:12 ET | 9000 | 45.255 |
| 12:14 ET | 2930 | 45.26 |
| 12:16 ET | 13622 | 44.88 |
| 12:18 ET | 836 | 44.82 |
| 12:20 ET | 5049 | 44.7275 |
| 12:21 ET | 2347 | 44.73 |
| 12:23 ET | 5200 | 44.66 |
| 12:25 ET | 9988 | 44.89 |
| 12:27 ET | 15730 | 45.19 |
| 12:30 ET | 1400 | 45.08 |
| 12:32 ET | 4894 | 45 |
| 12:34 ET | 1385 | 45.13 |
| 12:36 ET | 476 | 45.05 |
| 12:38 ET | 5333 | 44.7 |
| 12:39 ET | 300 | 44.79 |
| 12:41 ET | 1500 | 44.8 |
| 12:43 ET | 4330 | 44.796 |
| 12:45 ET | 100 | 44.63 |
| 12:48 ET | 100 | 44.7 |
| 12:50 ET | 3522 | 44.7 |
| 12:52 ET | 2386 | 44.695 |
| 12:54 ET | 3266 | 44.74 |
| 12:56 ET | 4124 | 44.715 |
| 12:57 ET | 3055 | 44.85 |
| 12:59 ET | 2226 | 45.02 |
| 01:01 ET | 3331 | 44.886 |
| 01:03 ET | 672 | 44.865 |
| 01:06 ET | 4730 | 44.67 |
| 01:08 ET | 3114 | 44.645 |
| 01:10 ET | 4969 | 44.7 |
| 01:12 ET | 1058 | 44.68 |
| 01:14 ET | 1872 | 44.7 |
| 01:17 ET | 7127 | 44.97 |
| 01:19 ET | 800 | 44.965 |
| 01:21 ET | 3250 | 45.015 |
| 01:24 ET | 10694 | 44.94 |
| 01:26 ET | 500 | 44.835 |
| 01:28 ET | 100 | 44.845 |
| 01:30 ET | 2299 | 44.995 |
| 01:32 ET | 2838 | 44.97 |
| 01:33 ET | 1188 | 44.91 |
| 01:35 ET | 600 | 44.85 |
| 01:37 ET | 300 | 44.87 |
| 01:39 ET | 2079 | 44.94 |
| 01:42 ET | 500 | 44.95 |
| 01:44 ET | 2600 | 44.93 |
| 01:46 ET | 2990 | 45.04 |
| 01:48 ET | 600 | 45.06 |
| 01:50 ET | 900 | 45.01 |
| 01:51 ET | 1600 | 45.09 |
| 01:53 ET | 1550 | 45.15 |
| 01:55 ET | 7246 | 45.33 |
| 01:57 ET | 4953 | 45.16 |
| 02:00 ET | 3650 | 45.17 |
| 02:02 ET | 1255 | 45.17 |
| 02:04 ET | 3539 | 45.155 |
| 02:06 ET | 800 | 45.16 |
| 02:08 ET | 2402 | 45.22 |
| 02:09 ET | 800 | 45.22 |
| 02:11 ET | 600 | 45.22 |
| 02:13 ET | 3569 | 45.145 |
| 02:15 ET | 3424 | 45.145 |
Today
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS), from 2 hours ago by Dow Jones
2 hours ago by Dow JonesCrinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
May 30, 2024
Press Release: Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs, from 4:05PM ET on Thursday May 30, 2024 by Dow Jones
4:05PM ET on Thursday May 30, 2024 by Dow JonesCrinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs, from 4:05PM ET on Thursday May 30, 2024 by Dow Jones
4:05PM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
DJ Crinetics Pharmaceuticals Is Maintained at Outperform by Baird, from 12:48PM ET on Thursday May 23, 2024 by Dow Jones
12:48PM ET on Thursday May 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.5B | -12.0x | --- |
Immunovant Inc | 3.7B | -13.5x | --- |
Merus NV | 3.6B | -19.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Dyne Therapeutics Inc | 3.1B | -7.9x | --- |
Biohaven Ltd | 3.1B | -5.0x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5B |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 1,774.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
